Ann E. Stapleton.and her colleagues conducted a randomized double-blind phase 2
study for assessing the impact of pro-biotic in preventing and controlling
occurrences of urinary tract infection.
The intravaginal application of probiotic consisting of Lactobacillus
crispatus CTV-05 or Lactin-V
Inc have proved
to be beneficial in limiting the recurrence of urinary tract infection (UTI) by almost fifty percent in UTI- susceptible women.
Significantly large studies are needed to
necessitate the replacement of long prevalent antimicrobial preventive methods
by vaginal Lactobacillus in prone females.
Ann Stapleton, MD, in the Washington University,
Seattle, observed that the females with
UTI occurring tendencies have a deranged vaginal flora that leads to decrease in
It was noted in phase 1 of the study of Lactin-V that administration of the probiotic as
vaginal suppository in females with recurrent UTI history resulted in minimum
. 100 premenopausal females with prior UTI history (median
age 21 years) in the phase 2 study, were given antimicrobial drugs and later on
randomly picked to either use placebo
vaginal suppository or ( Lactin-V . The treatment was given once a day for 5 days. Follow up
was done weekly for 10 weeks.
Stapleton's study revealed that recurrent UTI was seen to occur in only 7 (15%) of 48 ladies receiving Lactin-V
while with placebo the recurrent
UTI was seen in 13 (27%) females.
Studies established the relative risk [RR], .5; 95% confidence interval
[CI], .2 - 1.2).
Dr. Stepleton reported that the apprehensions associated with use of
Lactin-V were almost identical to that of antimicrobial drugs in majority of
follow up was related with significant level of colonization and major decrease
in recurrentUTI in females receiving
Lactin-V.The phase 1 study
revealed that the safety profile of the women getting Lactobacillus crispatus
CTV-05 and placebo was almost identical ( 56% vs 50%) The common side effects in both groups were - Vaginal discharge, abdominal discomfort and
The most outstanding feature was that the females treated with placebo
were found to have high concentrations of vaginal L. crispatus but were
still prone to recurrent UTI (RR, 1.1; 95% CI, .4 - 3.1). However females who underwent
treatment with Lactin-V were well protected against recurrent UTI (RR, .07; 95%
CI, .02 - .3; P
The conclusion drawn was that in the treatment of UTI, Lactin-V has advantage over vaginal
microbiota regeneration brought about by endogenous L. crispatus
. The creation of better understanding of
protection mechanism and optimization of an adequate prophylactic regime was
also possible with this study.
The study was published in. Clinical Infectious
Diseases 2011, and was conducted by Ann E. Stapleton,Melissa Au-Yeung, Thomas
M. Hooton, David N. Fredricks, Pacita L. Roberts, Christopher A. Czaja, Yuliya
Yarova-Yarovaya,1 Tina Fiedler, Marsha Cox, and Walter E. Stamm